A Randomized Double-Blind, Placebo-Controlled, Crossover to Open Label, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® AFIS Inline System in Mechanically Ventilated Patients With Gram-negative and/or Gram-positive Bacterial Colonization
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2015
Price : $35 *
At a glance
- Drugs Amikacin/fosfomycin (Primary)
- Indications Pneumonia
- Focus Therapeutic Use
- Sponsors Cardeas Pharma
- 17 Nov 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 28 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 09 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Jan 2016, according to to ClinicalTrials.gov record.